Active Stocks: Electromed, Egalet Corp, Echo Therapeutics, Atossa Genetics, CombiMatrix Corp.
By Josh Gee   
Wednesday, 24 September 2014 16:43

U.S. stocks rose Wednesday, with the Dow rebounding after two sessions of losses. The Dow Jones Industrial Average gained 102 points, or 0.6%, to 17158.

The S&P 500 index added 10 points, or 0.5%, to 1993 and the Nasdaq Composite rose 34 points, or 0.8%, to 4543. Stocks of small companies also recovered. The Russell 2000 rose 0.5% to 1124, following a 0.9% decline on Tuesday. The index lost 3.5% in the three sessions ended Tuesday.


Thinly-traded nano cap Electromed, Inc. (NYSEMKT:ELMD) pops on a 20x surge in volume albeit on turnover of only 400K shares. The company reported Q4 and FY results yesterday after the close.

Thinly-traded nano cap Egalet Corp. (NASDAQ:EGLT) plummets on a 4x surge in volume albeit on turnover of only 99K shares. At the close yesterday, the company reported that it will need to conduct additional clinical trials for Egalet-001, its abuse deterrent extended release oral morphine product candidate. In a crossover pharmacokinetic study, Egalet-001 failed its bioequivalence endpoint at the 90% CI (confidence interval).

Citing insufficient liquidity, Echo Therapeutics Inc. (NASDAQ:ECTE) suspends its operations. The resumption of operations will be dependent on securing additional third party funding.

Thinly-traded nano cap Atossa Genetics Inc. (NASDAQ:ATOS) gets smacked down on a 10x surge in volume after the FDA says it will have to resubmit a 510(k) application for its ForeCYTE Breast Aspirator.

Traders push shares of nano cap CombiMatrix Corp. (NASDAQ:CBMX) up this morning on 2x higher volume on no news. Coattailers might want to keep their powder dry for a while, though. The stock is still mired in the throes of a 10-year down trend. Prices peaked at a reverse split-adjusted $930 in late January 2004.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus